Pharmacy Daily | New option for acne

NEW Zealand-based dairy biotechnology firm Quantec has presented encouraging results from a US clinical trial on acne, utilising the company’s patented complex of “bioactive milk proteins” called IDP. Attendees at last weeks’ NZ Dermatological Society Annual Meeting which took place on the Qld Sunshine Coast heard about the trial where IDP was the active ingredient in a specially formulated skin cream which went headto- head in a double blind study against a premium US-based clinical brand of acne treatment cream, containing 2% salicylic acid plus retinal. At the conclusion of the 42- day trial involving 84 subjects, both creams showed statistically equivalent results in terms of total reduction in acne lesions; however the IDP-based cream showed a major improvement of over 52% in reduction of redness and inflammation. The clinical assessment saw the IDP product also pass specific testing for use on subjects with sensitive skin. Quantec founder and md Rod Claycomb said that the bio-proteins in IDP are powerful against certain types of disease-causing bacteria while leaving the natural and beneficial bacteria of the skin largely unaffected, with the product the result of seven years of development and testing. He said it was important for the company to unveil IDP and its efficacy as an acne treatment to dermatologists prior to developing and commercialising a commercial acne product.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13